Truly “Focused on Faster” For Aseptic Filling
Rethinking Aseptic Filling: Innovations To Meet Pharma’s Challenging Requirements
Microbiology Fulfills A Vital QC Role At A CDMO In Aseptic Filling And Sampling
How Efficient Batch Records Serve Thorough Tech Transfer — Optimizing Aseptic Fill For Development Projects
Approach To Simplifying Aseptic Contract Manufacturing – Part 2: Documentation
Approach To Simplifying Aseptic Contract Manufacturing
Advancing Aseptic Filling: Evaluating The Revolutionary SA25 Workcell
Scheduling Aseptic Filling for Preclinical and Clinical Batches
Strategies to Maximize Batch Yields in Aseptic Manufacturing: High Value Actives
Advances in drug and biologics discovery have allowed the development of increasingly sophisticated and highly targeted therapeutics. The active ingredients, whether small molecules or biologics, have become increasingly complex and costly to manufacture. Because of the physical properties of most biologics, the route of administration is typically parenteral and therefore it is imperative that manufacturers of sterile drug product develop strategies to maximize their yields and minimize losses throughout the finished product production process. Here are a number of considerations:










